52nd week of 2020 patent applcation highlights part 28 |
Patent application number | Title | Published |
20200399598 | IL-33 SECRETING IMMUNORESPONSIVE CELLS AND USES THEREOF - The present disclosure provides methods and compositions for enhancing the immune response toward cancers and pathogens. It relates to an immunoresponsive cell comprising an antigen-recognizing receptor (e.g., a chimeric antigen receptor (CAR) or a T cell receptor (TCR)), and expressing increased level of IL-33. In certain embodiments, the engineered immunoresponsive cells are antigen-directed and have enhanced immune-activating properties. | 2020-12-24 |
20200399599 | METHOD FOR GENERATING CELLS OF THE T CELL LINEAGE - A method of generating cells of the T cell lineage is provided comprising (a) culturing a sample comprising stem cells or progenitor cells with a Notch ligand conjugated to a suspension support and (b) isolating cells of the T cell lineage. In one embodiment, the cells of the T-cell lineage are progenitor T cells or mature T cells. Compositions, kits and uses thereof are also provided. | 2020-12-24 |
20200399600 | Methods for Preparing Therapeutically Active Cells Using Microfluidics - The present invention is directed to the use of microfluidics in the preparation of cells and compositions for therapeutic uses. | 2020-12-24 |
20200399601 | DIFFERENTIATION OF MACROPHAGES FROM PLURIPOTENT STEM CELLS - The present invention relates to a method of culturing primitive macrophages from stem cells. Specifically, the method comprises contacting and incubating stem cells with a serum-free culture media comprising a GSK3 inhibitor to differentiate stem cells into cell of the mesoderm lineage, contacting and incubating cells of the mesoderm lineage with a culture media comprising DKK1 to differentiate the cells into the hematopoietic lineage, maturing the cells of the hematopoietic lineage and contacting and incubating these cells with a culture media comprising M-CSF to drive differentiation into primitive-like macrophages. The invention also relates to a primitive-like macrophage, use of the primitive-like macrophage and a kit when used in the method of the invention. | 2020-12-24 |
20200399602 | Method for Differentiation of Human Pluripotent Stem Cell Lines in Suspension Culture - Methods of differentiation of pluripotent stem cells into hematopoietic precursor cells, wherein the method is carried out under suspension agitation, and wherein a GSK-3-inhibitor or a Wnt pathway activator is added during a stage of mesoderm induction, and cell culture media for use in the methods, as well as kits for performing the same. | 2020-12-24 |
20200399603 | BROWN FAT CELLS AND METHOD FOR PREPARING SAME - This invention provides a method for preparing a brown adipocyte from a somatic cell of a mammal by introducing at least one brown adipocyte-related gene or expression product thereof and at least one reprogramming-related gene or expression product thereof into the somatic cell, the brown adipocyte-related gene being at least one member selected from the group consisting of PRDM16(P) and C/EBPβ(C), the reprogramming-related gene being at least one member selected from the group consisting of Myc family genes (c-Myc(M), N-Myc, L-Myc(L), S-Myc, and B-Myc), GLIS family genes (GLIS1 (G), GLIS 2, and GLIS 3), Klf family genes (KLF1, KLF2, KLF3, KLF4(K), KLF5, KLF6, KLF7, KLF8, KLF9, KLF10, KLF11, KLF12, KLF13, KLF14, KLF15, KLF16, and KLF17), Oct family genes, Sox family genes, and Lin-28. | 2020-12-24 |
20200399604 | SYSTEM AND METHOD FOR EXTRACTION AND CRYOPRESERVATION OF BONE MARROW - Methods are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation and for obtaining desired cells from cryopreserved and fresh bone marrow. | 2020-12-24 |
20200399605 | SYSTEM AND METHOD FOR EXTRACTION AND CRYOPRESERVATION OF BONE MARROW - Methods are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation and for obtaining desired cells from cryopreserved and fresh bone marrow. | 2020-12-24 |
20200399606 | SYSTEM AND METHOD FOR EXTRACTION AND CRYOPRESERVATION OF BONE MARROW - Methods are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation and for obtaining desired cells from cryopreserved and fresh bone marrow. | 2020-12-24 |
20200399607 | SYSTEM AND METHOD FOR EXTRACTION AND CRYOPRESERVATION OF BONE MARROW - Methods are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation and for obtaining desired cells from cryopreserved and fresh bone marrow. | 2020-12-24 |
20200399608 | SYSTEM AND METHOD FOR EXTRACTION AND CRYOPRESERVATION OF BONE MARROW - Methods are provided for extracting bone marrow cells from bone obtained from deceased donors, for preparing the bone marrow for cryopreservation and for obtaining desired cells from cryopreserved and fresh bone marrow. | 2020-12-24 |
20200399609 | SELF REPLICATING RNA FOR INDUCING SOMATIC DIFFERENTIATION OF UNMODIFIED ADULT STEM CELLS - A self-replicating RNA for inducing somatic differentiation of unmodified adult stem cells is described. Methods of differentiating unmodified adult stem cells into functional beta-like cells are also described, as well as compositions, tissues and devices containing such cells. The method requires inducing sequential expression of PDX1 before NGN3, and NGN3 before MAFA in these stem cells to form reprogrammed beta-cells. Self-replicating RNAs are provided and introduced into the adult stem cells to induce the sequential expression. Methods of treating diabetes are also provided, comprising obtaining stem cells, preferably from a patient with diabetes, inducing sequential expression of PDX1>NGN3>MAFA, in said stem cells to form reprogrammed beta-cells, and introducing said reprogrammed beta-cells into a pancreas of said patient. | 2020-12-24 |
20200399610 | MATERIALS AND METHODS FOR GENERATING THERAPEUTIC MESENCHYMAL STEM CELLS - Embodiments of the present disclosure relate generally to the production of therapeutic mesenchymal stem cells (MSCs). More particularly, the present disclosure relates to the use of cell culture compositions and methods for generating MSCs that secrete neurotrophic factors and synaptic organizing agents for the treatment of neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS). As such, the present disclosure addresses the need for establishing a reliable source of therapeutic stem cells useful for the treatment of neurodegenerative diseases. | 2020-12-24 |
20200399611 | MICROENVIRONMENTS FOR SELF-ASSEMBLY OF ISLET ORGANOIDS FROM STEM CELLS DIFFERENTIATION - Human pluripotent stem cells (hPSCs) are promising cell source to produce therapeutic endocrine cells for diabetes treatment. A gel solution made by decellularized tissue-specific extracellular matrix (dpECM) significantly promotes three-dimensional (3D) islet-like organogenesis during induced hPSC differentiation into endocrine lineages. Islet organoids are self-organized even in a two-dimensional (2D) culture mode. Cells derived from hPSCs differentiated on such ECM coated substrates exhibit similar cellular composition to native pancreatic islets. These cells express islet signature markers insulin, PDX-1, C-peptide, MafA, glucagon, somatostatin, and pancreatic polypeptide, and secrete more insulin in response to glucose level compared to a traditional matrix substrate (Matrigel). The dpECM facilitates generating more C-peptide+/glucagon− cells rather than C-peptide+/glucagon+ cells. Remarkably, dpECM also facilitated intra-organoid vascularity by generating endothelial cells and pericytes. Furthermore, dpECM niches also induced intra-organoid microvascularization during pancreatic differentiation. | 2020-12-24 |
20200399612 | LIGHT MOUNTING SYSTEMS AND METHODS - Embodiments disclosed herein describe systems and methods associated with light mounting systems. Embodiments may include lighting shelves that are configured to be mounted to a fixed structure, such as to a wall or supports within a room via a cantilever design that is mounted to strut channels. The lighting shelves may be anchored at only a single end to the strut channels, and the lighting shelves may protrude away from the strut channels. The lighting shelves may have a sufficient width and length to cover an entire region of interest below the lighting shelves, which may enable to lighting shelves to uniformly distribute light to plants. | 2020-12-24 |
20200399613 | Cell Mass Fusion Method - The present invention provides a method of fusing cell masses. A method of fusing cell masses, comprising seeding cell masses on a plane capable of cell adhesion and culturing the cell masses as a culture medium is fed from both the obverse and reverse sides of the cell mass-seeded plane. | 2020-12-24 |
20200399614 | Methods for Producing Mutant Bacteriophages for the Detection of Listeria - Disclosed herein are methods for the production of mutant bacteriophages with altered host range. Additionally, disclosed herein are methods and systems for rapid detection of microorganisms such as | 2020-12-24 |
20200399615 | Enhanced adoptive cell therapy - The present invention relates to the fields of life sciences and medicine. Specifically, the invention relates to cancer therapies of humans. More specifically, the present invention relates to oncolytic adenoviral vectors alone or together with therapeutic compositions for therapeutic uses and therapeutic methods for cancer. In one aspect the present invention relates to separate administration of adoptive cell therapeutic composition and oncolytic adenoviral vectors. Furthermore, the present invention relates to a pharmaceutical kit and a pharmaceutical composition, both utilizing oncolytic adenoviral vectors. | 2020-12-24 |
20200399616 | ENGINEERED IMINE REDUCTASES AND METHODS FOR THE REDUCTIVE AMINATION OF KETONE AND AMINE COMPOUNDS - The present application provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds. | 2020-12-24 |
20200399617 | B4GALT1 Variants And Uses Thereof - Variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of detecting the presence of these molecules, methods of modulating endogenous B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, methods of ascertaining the risk of developing cardiovascular conditions by detecting the presence or absence of the variant B4GALT1 genomic, mRNA, and cDNA nucleic acid molecules, and polypeptides, and methods of treating cardiovascular conditions are provided herein. | 2020-12-24 |
20200399618 | Compositions and Methods for Pesticide Degradation - Compositions and methods related to anucelate cells (e.g., bacterial minicells) for pesticide degradation applications including related cells, polypeptides, and vectors. | 2020-12-24 |
20200399619 | EDITING OF CCR5 RECEPTOR GENE TO PROTECT AGAINST HIV INFECTION - Provided herein are systems, compositions, and methods of introducing protective and/or loss-of-function variants of CCR5 and CCR2. Variants may be introduced using a CRISPR/Cas9-based nucleobase editor or other guide nucleotide sequence-programmable DNA binding protein domain-based fusion protein described herein. Further provided herein are compositions and methods of preventing and treating conditions related to HIV infection and progression as well as to AIDS. | 2020-12-24 |
20200399620 | Engineered CRISPR-Cas9 nucleases with Altered PAM Specificity - Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting. | 2020-12-24 |
20200399621 | Engineered CRISPR-Cas9 nucleases with Altered PAM Specificity - Engineered CRISPR-Cas9 nucleases with altered and improved PAM specificities and their use in genomic engineering, epigenomic engineering, and genome targeting. | 2020-12-24 |
20200399622 | ENGINEERED DNASE ENZYMES AND USE IN THERAPY - The present invention provides engineered DNase proteins (including DNase1-like 3 and DNase1) that are useful for treating conditions characterized by neutrophil extracellular trap (NET) accumulation and/or release. In some aspects, the invention provides compositions and methods for preventing or treating vascular occlusion involving NETs. As demonstrated herein, NETs participate in a non-canonical mechanism for vascular occlusion, which is not dependent on fibrin or platelets. | 2020-12-24 |
20200399623 | METHODS AND COMPOSITIONS FOR THERAPEUTIC PROTEIN DELIVERY - Compositions and methods for delivering a therapeutic protein to the central nervous system (CNS), in order to treat diseases and disorders that impair the CNS, such as treating lysosomal storage diseases are disclosed. Therapeutic proteins delivered via a therapeutically effective amount of a nucleotide composition encoding the therapeutic protein conjugated to a cell surface receptor-binding protein that crosses the blood brain barrier (BBB) are provided. | 2020-12-24 |
20200399624 | OXIDATION STABLE ALPHA-AMYLASE VARIANTS - The present invention relates to oxidation stable alpha-amylase variants. The present invention also relates to polynucleotides encoding the variants; nucleic acid constructs, vectors, and host cells comprising the polynucleotides; and methods of using the variants. | 2020-12-24 |
20200399625 | Polypeptides Having Lysozyme Activity and Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having lysozyme activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides. | 2020-12-24 |
20200399626 | USES OF ADENOSINE BASE EDITORS - The disclosure provides methods and compositions for treating blood diseases/disorders, such as sickle cell disease, hemochromatosis, hemophilia, and beta-thalassemia. For example the disclosure provides therapeutic guide RNAs that target the promotor of HBG1/2 to generate point mutations that increase expression of fetal hemoglobin. As another example, the disclosure provides therapeutic guide RNAs that target mutations in HBB, Factor VIII, and HFE to treat sickle cell disease, beta-thalassemia, hemophilia and hemochromatosis. The disclosure also provides fusion proteins comprising a Cas9 (e.g., a Cas9 nickase) domain and adenosine deaminases that deaminate adenosine in DNA. In some embodiments, the fusion proteins are in complex with nucleic acids, such as guide RNAs (gRNAs), which target the fusion proteins to a DNA sequence (e.g., an HBG1 or HBG2 protmoter sequence, or an HFE, GBB, or F8 gene sequence). Such complexes may be useful for increasing expression of fetal hemoglobin or correcting a poing mutation (e.g., C282Y) in HFE. | 2020-12-24 |
20200399627 | ENGINEERED PHENYLALANINE AMMONIA LYASE POLYPEPTIDES - The present invention provides engineered phenylalanine ammonia-lyase (PAL) polypeptides and compositions thereof, as well as polynucleotides encoding the engineered phenylalanine ammonia-lyase (PAL) polypeptides. | 2020-12-24 |
20200399628 | FORMULATIONS AND DOSES OF PEGYLATED URICASE - Provided herein are methods and compositions and kits related to identification and/or treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout, and for preventing gout flare. | 2020-12-24 |
20200399629 | METHOD FOR REDUCING IMMUNOGENICITY OF RNA - The present invention relates to RNA therapy and, in particular, decreasing immunogenicity of RNA. Specifically, the present invention provides methods for decreasing immunogenicity of RNA, said methods comprising modifying the nucleotide sequence of the RNA by reducing the uridine (U) content, wherein said reduction of the U content comprises an elimination of U nucleosides from the nucleotide sequence of the RNA and/or a substitution of U nucleosides by nucleosides other than U in the nucleotide sequence of the RNA. Using RNA having decreased immunogenicity allows administration of RNA as a drug to a subject, e.g. in order to obtain expression of a pharmaceutically active peptide or protein, without eliciting an immune response which would interfere with therapeutic effectiveness of the RNA or induce adverse effects in the subject. | 2020-12-24 |
20200399630 | PEPTIDE LIBRARIES - The invention relates to novel libraries of linear and cyclic peptides, and methods of generating and screening such libraries for biological, pharmaceutical and other uses. | 2020-12-24 |
20200399631 | Methods and Compositions for Sample Analysis - The present disclosure relates to methods and systems for sample processing and analyzing when the total quantity of input sample is low or when a target of interest is present as a relatively minor or rare population within the overall sample. The disclosure particularly relates to analyzing nucleic acid samples, including samples where a target nucleic acid of interest is present as a relatively low proportion of the overall nucleic acids. | 2020-12-24 |
20200399632 | SENSOR SYSTEMS - The present technology relates to methods and compositions that provide for improved detection of target molecules in, for example, bioengineering. | 2020-12-24 |
20200399633 | OLIGONUCLEOTIDE-TETHERED NUCLEOTIDES - The present disclosure describes oligonucleotide-tethered nucleotides, methods of making them, and methods of using them. The oligonucleotide-tethered nucleotides comprise, in some embodiments, a nucleotide linked to an oligonucleotide of from about 3 to about 100 nucleotides in length. These oligonucleotide-tethered nucleotides can be used to label a plurality of different types of nucleic acids in a plurality of different situations with a known oligonucleotide, which can serve as a barcode in some embodiments. The resulting oligonucleotide-labeled nucleic acids oligonucleotides can be used in a variety of nucleic acid sequencing methods. | 2020-12-24 |
20200399634 | DNA-TEMPLATED MACROCYCLE LIBRARY - The present invention provides nucleic acid templates (e.g., including orthogonal codon sets (e.g., codons from orthogonal codon sets depicted in Tables 5 or 7)) for DNA-templated methods of synthesizing, selecting, and amplifying compounds (e.g., polymers and/or small molecules) described herein. Also provided are novel macrocyclic compounds of Formula (I), and pharmaceutically acceptable salts, solvates, hydrates, polymorphs, co-crystals, tautomers, stereoisomers, isotopically labeled derivatives, prodrugs, libraries, and compositions thereof. Also provided are methods and kits involving the inventive compounds or compositions for treating and/or preventing a disease (e.g., a disease associated with aberrant enzyme activity (e.g., aberrant protease and/or kinase activity (e.g., aberrant IDE activity)), impaired insulin signaling, or insulin resistance in a subject (e.g., a subject having diabetes). Treatment of a subject with a proliferative disease using a compound or composition of the invention may inhibit aberrant protease activity (e.g., aberrant IDE activity). | 2020-12-24 |
20200399635 | COMPOSITIONS AND METHODS FOR MOLECULAR LABELING - The invention provides barcode libraries and methods of making and using them including obtaining a plurality of nucleic acid constructs in which each construct comprises a unique N-mer and a functional N-mer and segregating the constructs into a fluid compartments such that each compartment contains one or more copies of a unique construct. The invention further provides methods for digital PCR and for use of barcode libraries in digital PCR. | 2020-12-24 |
20200399636 | Method, system and device for automated NGS library preparation - Disclosed is an enclosed magnetic beads-based reaction system for automation of multi-step DNA preparation process involving DNA purification, modification and amplification. It is especially suitable for making DNA library preparation for next-generation sequencing. It uses modules to perform steps of the multi-step reaction and uses magnetic beads to carry DNA to travel through modules to accomplish the multi-step process. The operation can be fully automated, saving time and repetitive hands-on operations and reducing human errors. Using the enclosed reaction system allows parallel processing of different samples and avoids cross-contamination. | 2020-12-24 |
20200399637 | LOSS OF FUNCTION ALLELES OF PtEPSP-TF AND ITS REGULATORY TARGETS IN RICE - The present disclosure provides genetically modified plants, plant cells and plant tissues that show reduced lignin content as compared to a control plant which was not genetically modified. In addition, the disclosure provides methods of regulating lignin content in a plant. The disclosure also provides methods of producing bioproducts using the genetically modified plants of the instant disclosure. | 2020-12-24 |
20200399638 | OLIGONUCLEOTIDES MATCHING COL7A1 EXON 73 FOR EPIDERMOLYSIS BULLOSA THERAPY - Antisense oligonucleotides capable of preventing or reducing exon 73 inclusion into the human COL7A mRNA are characterized in various ways: (a) the oligonucleotide's sequence includes at most two CpG sequences; (b) the oligonucleotide has a length of no more than 24 nucleotides; (c) the oligonucleotide is capable of annealing to the (SRp40/SC35 binding/ESE) element in exon73. These oligonucleotides can usefully be oligoribonucleotides with modified internucleosidic linkages e.g. phosphorothioate linkages. | 2020-12-24 |
20200399639 | DETECTION OF MICROBIAL ENDOTOXINS IN ORAL SAMPLES USING APTAMERS - The present invention is directed to an aptamer composition comprising at least one oligonucleotide consisting of: deoxyribonucleotides, ribonucleotides, derivatives of deoxyribonucleotides, derivatives of ribonucleotides, and mixtures thereof; wherein said aptamer composition has a binding affinity for one or more bacterial species from the genera | 2020-12-24 |
20200399640 | TREATMENT OF ANGIOPOIETIN LIKE 7 (ANGPTL7) RELATED DISEASES - Provided herein are oligonucleotide compositions that inhibit ANGPTL7 and reduce intraocular pressure when administered to an eye. The oligonucleotide compositions contain nucleoside modifications. | 2020-12-24 |
20200399641 | ANTISENSE OLIGONUCLEOTIDES FOR MODULATING HTRA1 EXPRESSION - The present invention relates to antisense oligonucleotides (oligomers) that are complementary to HTRA1, leading to modulation of the expression of HTRA1. Modulation of HTRA1 expression is beneficial for a range of medical disorders, such as macular degeneration, e.g. age-related macular degeneration. | 2020-12-24 |
20200399642 | METHODS AND COMPOSITIONS FOR TREATING AND PREVENTING METASTATIC TUMORS - Some embodiments of the methods and compositions provided herein relate to the treatment and amelioration of metastatic tumors and to the prevention of distant metastasis. In some embodiments, a metastatic tumor, such as a melanoma, can be treated by reducing the activity of NOX2 in a cell of a subject. In some embodiments, the activity of NOX2 can be reduced by administering a NOX2 inhibitor, such as histamine dihydrochloride (HDC). | 2020-12-24 |
20200399643 | P38 MAP KINASE INHIBITORS - Provided herein, inter alia, are p38 mitogen-activated protein kinase inhibitors and methods of treating cancer using p38 mitogen-activated protein kinase inhibitors | 2020-12-24 |
20200399644 | CCR3 MODULATION IN THE TREATMENT OF AGING-ASSOCIATED IMPAIRMENTS, AND COMPOSITIONS FOR PRACTICING THE SAME - Methods of treating an adult mammal for an aging-associated impairment are provided. Aspects of the methods include modulating CCR3, e.g., by modulating eotaxin-1/CCR3 interaction, in the mammal in a manner sufficient to treat the mammal for the aging-associated impairment. A variety of aging-associated impairments may be treated by practice of the methods, which impairments include cognitive impairments. | 2020-12-24 |
20200399645 | OPTIMIZED VECTOR FOR DELIVERY IN MICROBIAL POPULATIONS - The present invention relates to a vector, preferably included in a delivery vehicle, comprising no more than 100, preferably no more than 10, restriction sites recognized by the restriction enzymes encoded by each bacterium of a group of bacteria of interest. The invention also relates to the use of said vector, preferably included in a delivery vehicle, as a drug, especially in the treatment of a disease in a patient in need thereof. | 2020-12-24 |
20200399646 | CONSTRUCTS AND CELLS FOR ENHANCED PROTEIN EXPRESSION - Described are expression constructs, cells, and methods of producing proteins in | 2020-12-24 |
20200399647 | GENOME EDITING BY POLLEN-MEDIATED TRANSFORMATION - Disclosed herein are methods of genome-editing transformation that delivers to the cell the RNA-guided endonucleases as well as the required guide RNA, without the need of tissue culture to regenerate the plant. Thus, methods as described herein enable any plant species to have its genome edited in a process that is simple and efficient. This process utilizes genome-editing pollen cells, and delivering the required components for the editing by combining them with cell-penetrating peptides. | 2020-12-24 |
20200399648 | COMPOSITIONS AND METHODS FOR MODIFICATION OF FATTY ACIDS IN SOYBEAN - Methods and compositions to modify the fatty acid profiles of seeds and the oils produced therefrom include the modification of four or more alleles of fatty acid desaturases in the genome of a plant. Compositions, polynucleotide constructs, transformed and modified host cells, and plants and seeds exhibiting altered fatty characteristics are provided. | 2020-12-24 |
20200399649 | ORGANISMS AND METHODS FOR PRODUCING GLYCOMOLECULES WITH LOW SULFATION - The invention provides recombinant organisms containing a nucleic acid encoding a heterologous glycomolecule that has a low sulfation profile or that is unsulfated. In one embodiment the heterologous glycomolecule is an immunoglobulin molecule. The recombinant organisms have a genetic modification to at least one sulfotransferase gene, such as a deletion, disruption, or other genetic modification. The cells advantageously produce and, optionally secrete, the heterologous glycomolecule. Thus, the invention provides recombinant organisms that provide glycomolecules having a glycosylation profile that is more similar to the glycosylation profile produced in a mammalian cell, and therefore may be safer and more effective for use as a therapeutic in humans or animals. The glycomolecules can be a glycoprotein, glycopeptide, or a glycolipid. | 2020-12-24 |
20200399650 | METHODS FOR GENERATING CROP YIELD TRAITS - The present technology relates to a method for generating crop yield traits. The method comprises identifying a multi-genic system associated with one or more gene of interest, wherein the one or more gene of interest is operatively linked to yield of crop. Identifying at least one combination of genes within the multi-genic system that yields an active multi-protein system of interest and generating mutational diversity on the at least one combination of genes to generate a library. The method further comprises screening the library to identify mutations yielding an improved activity of multi-protein system of interest in an expression system and introducing the screened mutations into the crop. | 2020-12-24 |
20200399651 | PLANTS HAVING INCREASED TOLERANCE TO HERBICIDES - Provided is a plant or plant part comprising a polynucleotide encoding a mutant TriA polypeptide, the expression of the polynucleotide confers to the plant or plant part tolerance to herbicides | 2020-12-24 |
20200399652 | TBRFV RESISTANT TOMATO PLANT - The invention relates to a | 2020-12-24 |
20200399653 | INSECTICIDAL PROTEINS AND METHODS FOR THEIR USE - Compositions and methods for controlling pests are provided. The methods involve transforming organisms with a nucleic acid sequence encoding an insecticidal protein. In particular, the nucleic acid sequences are useful for preparing plants and microorganisms that possess insecticidal activity. Thus, transformed bacteria, plants, plant cells, plant tissues and seeds are provided. Compositions are insecticidal nucleic acids and proteins of bacterial species. The sequences find use in the construction of expression vectors for subsequent transformation into organisms of interest including plants, as probes for the isolation of other homologous (or partially homologous) genes. The pesticidal proteins find use in controlling, inhibiting growth or killing Lepidopteran, Coleopteran, Dipteran, fungal, Hemipteran and nematode pest populations and for producing compositions with insecticidal activity. | 2020-12-24 |
20200399654 | INSECTICIDAL PROTEIN DISCOVERY PLATFORM AND INSECTICIDAL PROTEINS DISCOVERED THEREFROM - The disclosure presents a platform for discovering novel insecticidal proteins from highly heterogeneous environmental sources. The methodology utilizes metagenomic enrichment procedures and unique genetic amplification techniques, which enables access to a broad class of unknown microbial diversity and their resultant proteome. The disclosed insecticidal protein discovery platform (IPDP) can be computationally driven and is able to integrate molecular biology, automation, and advanced machine learning protocols. The platform will enable researchers to rapidly and accurately access the vast repertoire of untapped insecticidal proteins produced by uncharacterized and complex microbial environmental samples. Also presented herein are a group of newly discovered pore-forming toxins (PFT) from a rare class of insecticidal proteins, which were discovered utilizing the insecticidal protein discovery platform. | 2020-12-24 |
20200399655 | OPTIMIZED LENTIVIRAL TRANSFER VECTORS AND USES THEREOF - The invention features lentiviral transfer vectors that include heterologous nucleic acids to be introduced into a cell. The lentiviral transfer vector may be characterized by the following features: (a) including a cytomegalovirus (CMV) promoter; (b) including a polynucleotide encoding a partial gag protein that includes a mutated INS1 inhibitory sequence that reduces restriction of nuclear export of RNA; (c) not including a polynucleotide encoding the INS2, INS3, and INS4 inhibitory sequences of gag; (d) not including an SV40 origin of replication and/or an f1 origin of replication; (e) including a cPPT sequence that contains splice site; (f) including an EF1alpha promoter with intact splice donor and acceptor sites; and (g) including hepatitis B PRE with mutation in start codon of X protein ORF. | 2020-12-24 |
20200399656 | Compositions and methods for enhancing functional expression of therapeutic genes in photoreceptors - Disclosed herein are nucleic acid regulatory elements, expression cassettes, expression vectors, and methods for using the nucleic acid regulatory elements, expression cassettes, expression vectors for treating cone cell disorders. | 2020-12-24 |
20200399657 | IMPROVED ADENO-ASSOCIATED VIRUS VECTOR - One disadvantage of adeno-associated virus (AAV) is low gene expression efficiency due to delayed expression of the inserted gene. Provided is a vector plasmid for producing a vector genome to be inserted into an adeno-associated virus (AAV). The vector plasmid is provided with a vector genome cassette as a template of the vector genome, and the vector genome cassette is provided with: (1) an expression cassette including a nucleic acid molecule encoding a target gene and (b) a nucleic acid molecule encoding an expression regulatory region that allows expression of the target gene; and (2) two nucleic acid molecules positioned on both sides of the expression cassette and encoding inverted terminal repeats (ITRs). Also provided is a pharmaceutical composition containing the AVV vector, for treating or preventing an eye disease or disease associated with same. Further provided is a method for treating or preventing the eye disease or disease associated with same, comprising administering a therapeutically effective amount of the pharmaceutical composition for treating or preventing the eye disease or disease associated with same to a subject suffering from the eye disease or disease associated with same. | 2020-12-24 |
20200399658 | ELECTROPORATION CUVETTES FOR AUTOMATION - The present disclosure relates to an electroporation device that may include many electroporation units and electroporation systems that can be used in an automated environment, e.g., as one station or module in a multi-station or multi-module cell processing environment. | 2020-12-24 |
20200399659 | HELPER PLASMID FOR TRANSFORMATION, METHOD FOR PRODUCING TRANSFORMANT USING THE SAME, AND TRANSFORMATION METHOD - A stable transformant, in which a gene of interest is incorporated into the genome, is simply and efficiently produced. | 2020-12-24 |
20200399660 | MODIFIED POLYAMINE POLYMERS FOR DELIVERY OF BIOMOLECULES INTO CELLS - Provided herein are compounds, compositions, and methods for delivering biomolecules to cells. In particular, the present disclosure provides modified polyamine polymers, including polyamine polymers having fluorinated substituents. | 2020-12-24 |
20200399661 | MATERIALS AND METHODS FOR PREVENTING TRANSMISSION OF A PARTICULAR CHROMOSOME - Provided herein are material and methods for changing gene expression in select sex chromosomes. The materials and methods of the subject invention can be used to produce non-human transgenic animals that produce progeny of a predetermined gender and to generate non-human transgenic animals that produce single-sexed semen. | 2020-12-24 |
20200399662 | ALKANE OXIDATION BY MODIFIED HYDROXYLASES - This invention relates to modified hydroxylases. The invention further relates to cells expressing such modified hydroxylases and methods of producing hydroxylated alkanes by contacting a suitable substrate with such cells. | 2020-12-24 |
20200399663 | HIGH PURITY STARCH STREAM METHODS AND SYSTEMS - Methods and systems for isolating a high purity starch stream are provided. The methods provide an initial treatment step in advance of traditional grinding or fractionation operations (such as dry milling or wet milling operations) that facilitate separation of starch from other components of starch-based grains, for example facilitate separation of soft endosperm from other components of corn kernels including hard endosperm. The systems include a first treatment system for separating a high purity starch stream from other components of the grain stream, wherein the system can be configured as a bolt on for traditional milling operations such as wet milling and dry milling operations. | 2020-12-24 |
20200399664 | PROCESSES AND SYSTEMS FOR METABOLITE PRODUCTION USING HYDROGEN RICH C1-CONTAINING SUBSTRATES - The invention is directed to a process for producing one or more fermentation product in a multi-stage process including an inoculation reactor and at least one bioreactor. The inoculation reactor is fed a C1-containing gaseous substrate containing a reduced amount of hydrogen. The hydrogen is reduced to increase the proportion of CO in the C1-containing gaseous substrate being provided to the inoculation reactor. The inoculation reactor ferments the CO-rich C1-containing gaseous substrate and produces an inoculum, which is fed to at least one bioreactor. The bioreactor receives the C1-containing gaseous substrate, which may or may not contain reduced amounts of hydrogen, to produce one or more fermentation product. By providing a CO-rich C1-containing gaseous substrate to the inoculation reactor, both the inoculation reactor and the subsequent bioreactor(s), are able to have increased stability and product selectivity. | 2020-12-24 |
20200399665 | PROCESSES FOR THE PRODUCTION OF HYDROXYCINNAMIC ACIDS USING POLYPEPTIDES HAVING TYROSINE AMMONIA LYASE ACTIVITY - The present invention generally relates to the field of biotechnology as it applies to the production of hydroxycinnamic acids using polypeptides having tyrosine ammonia lyase activity. More particularly, the present invention pertains to polypeptides having tyrosine ammonia lyase activity and high substrate specificity towards tyrosine, which makes them particularly suitable in the production of p-coumaric acid and other hydroxycinnamic acids. The present invention thus provides processes for the production of p-coumaric acid and other hydroxycinnamic acids employing these polypeptides as well as recombinant host cells expressing same. | 2020-12-24 |
20200399666 | METHOD FOR PREPARATION OF DIESTER DERIVATIVES OF MALONIC ACID - Methods for the preparation of bio-based malonic acid and diester derivatives of malonic acid are provided. The disclosed methods produce diester derivatives of malonic acid with fewer impurities, which is useful for many industrial processes. The diester derivatives of malonic acid can be purified from existing sources of malonic acid, or from malonic acid made from a renewable carbon source. | 2020-12-24 |
20200399667 | METHOD FOR EXTRACTING COENZYME Q10 AND PHOSPHOLIPID FROM COENZYME Q10 FERMENTATION BACTERIAL POWDER - The present application relates to a method for extracting coenzyme Q10 and a phospholipid from a coenzyme Q10 fermentation bacterium powder. The method is characterized in that the fermentation bacterium powder of a coenzyme Q10 production strain is subjected to extraction with a mixed solvent of which the three-dimensional Hansen solubility parameter is between 21 and 23 (J/cm | 2020-12-24 |
20200399668 | Polypeptides Having Alpha-Galactosidase Activity and Polynucleotides Encoding Same - The present invention relates to methods of releasing galactose from legumes using polypeptides having alpha-galactosidase activity. The invention also relates to polypeptides having alpha-galactosidase activity, polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing the polypeptides. The invention also relates to compositions comprising the polypeptides of the invention and the use of the polypeptides in animal feed. | 2020-12-24 |
20200399669 | Polypeptides Having Alpha-Galactosidase Activity and Polynucleotides Encoding Same - The present invention relates to methods of releasing galactose from legumes using polypeptides having alpha-galactosidase activity. The invention also relates to polypeptides having alpha-galactosidase activity, polynucleotides encoding the polypeptides, nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing the polypeptides. The invention also relates to compositions comprising the polypeptides of the invention and the use of the polypeptides in animal feed. | 2020-12-24 |
20200399670 | RECOMBINANT PRODUCTION METHOD - Herein is reported a method for the recombinant production of a polypeptide in a eukaryotic cell comprising the steps of (i) cultivating a eukaryotic cell comprising a nucleic acid encoding the polypeptide in a cultivation medium comprising a compound selected from the group consisting of trans-2-methyl 2-pentenoic acid, the broad-spectrum HDAC inhibitor Quisinostat, and the subtype-specific HDAC inhibitor Romidepsin, and (ii) recovering the polypeptide from the cell or the cultivation medium and thereby producing the polypeptide in a eukaryotic cell. | 2020-12-24 |
20200399671 | FUSION PROTEIN OF FLAVIN ADENINE DINUCLEOTIDE-GLUCOSE DEHYDROGENASE AND CYTOCHROME MOLECULE - The purpose of the present invention is to provide a fungus-derived FADGDH that has a direct electron transfer ability. Provided is a fusion protein comprising a fungus-derived FADGDH or a mutant thereof and a cytochrome molecule connected to the N-terminus of the FADGDH or variant thereof. | 2020-12-24 |
20200399672 | IMMUNOCHROMATOGRAPHIC ANALYSIS DEVICE FOR CHIKUNGUNYA VIRUS DETECTION - The present invention relates to an immunochromatographic analysis device for detecting chikungunya virus, including a sample loading part, a labeling substance retaining part, a chromatographic medium part having a detection part, and an absorption part, wherein the labeling substance retaining part contains a first antibody against the chikungunya virus, including a specific heavy chain variable region and a specific light chain variable region or an antigen-binding fragment thereof, and the detection part contains a second antibody against the chikungunya virus, including a specific heavy chain variable region and the light chain variable region or an antigen-binding fragment thereof, and a third antibody against the chikungunya virus, including a specific heavy chain variable region and the light chain variable region or an antigen-binding fragment thereof. | 2020-12-24 |
20200399673 | ASSESSING AND TREATING FUNCTIONAL GASTROINTESTINAL DISORDERS - This document relates to methods and materials involved in assessing and/or treating a mammal having a functional gastrointestinal disorder (FGID) such as irritable bowel syndrome (IBS). For example, methods and materials provided herein can be used for determining if a mammal having a FGID is likely to respond to a particular FGID treatment. This document also provides methods and materials for treating a mammal having a FGID. | 2020-12-24 |
20200399674 | DEVICES AND METHODS FOR SAMPLE PARTITIONING AND ANALYSIS - The present disclosure provides a device that includes a base comprising a substrate having a first major surface, a pressure sensitive adhesive adhered to at least a portion of the first major surface, a polymeric cover film coupled to the substrate via the adhesive, a plurality of isolated closed compartments disposed between the substrate and the cover film, and an aqueous liquid disposed in two or more of the closed compartments. The cover film is a composite film comprising ethylene vinyl acetate copolymer, a linear copolymer of ethylene and a higher alkene, and a tackifier. Each compartment of the plurality is defined by a seal that prevents liquid communication with at least one other compartment of the plurality. Methods of using the device for partitioning a sample, for analyzing a sample, and for culturing a microorganism are also provided. | 2020-12-24 |
20200399675 | DEVICES AND METHODS FOR EXAMINING DRUG EFFECTS ON MICROORGANISMS - The present invention provides devices, systems, and methods, for performing biological and chemical assays. | 2020-12-24 |
20200399676 | OPLOPHORUS-DERIVED LUCIFERASES, NOVEL COELENTERAZINE SUBSTRATES, AND METHODS OF USE - An isolated polynucleotide encoding a modified luciferase polypeptide and substrates. The OgLuc variant polypeptide has at least 60% amino acid sequence identity to SEQ ID NO: 1 and at least one amino acid substitution at a position corresponding to an amino acid in SEQ ID NO: 1. The OgLuc variant polypeptide has at least one of enhanced luminescence, enhanced signal stability, and enhanced protein stability relative to the corresponding polypeptide of the wild-type | 2020-12-24 |
20200399677 | METHODS FOR DIFFERENTIALLY QUANTIFYING NUCLEIC ACIDS - Methods for differentially quantifying nucleic acids in a biological sample using differentially methylated loci include forming a digested biological sample in a solution of a methylation-sensitive restriction enzyme to cleave an unmethylated group of nucleic acids, forming a reaction mixture, amplifying the reaction mixture to generate a first signal from the a group of detection probes and a second signal from a second group of detection probes, determining a ratio comprising a first value derived from the first signal to a second value derived from the second signal, and identifying the proportion of nucleic acid in the biological sample originating from the first plurality of nucleic acids. | 2020-12-24 |
20200399678 | METHOD FOR ANALYZING DNA METHYLATION USING NEXT GENERATION SEQUENCER AND METHOD FOR CONCENTRATING SPECIFIC DNA FRAGMENTS - This invention provides a technology of DNA methylation analysis including: | 2020-12-24 |
20200399679 | METHODS AND KITS FOR USING RECOMBINANT MICROORGANISMS AS DIRECT REAGENTS IN BIOLOGICAL APPLICATIONS - Disclosed herein is a method of utilizing an enzyme in a nucleic acid manipulation process, the method comprising: a) transforming a microorganism with a non-native enzyme; b) inducing expression of the enzyme in the microorganism, thereby producing the non-native enzyme; c) adding the microorganism of step b) directly to a non-naturally occurring nucleic acid manipulation process, wherein the non-native enzyme is not purified from the microorganism prior to addition to the nucleic acid manipulation process; and carrying out the nucleic acid manipulation process using the enzyme. Importantly, this method can be carried out without the need to purify the enzyme from the cell producing it before it is used in the nucleic acid manipulation method. Also disclosed herein is a kit for carrying out a nucleic acid manipulation process, the kit comprising a) a microorganism expressing a non-native enzyme; b) nucleic acids of interest; and c) reagents for use in the nucleic acid manipulation process. | 2020-12-24 |
20200399680 | NUCLEOTIDE SEQUENCE EXCLUSION ENRICHMENT BY DROPLET SORTING (NEEDLS) - The present invention pertains to an in vitro method in which a targeted DNA molecule containing a DNA sequence of interest is enriched by a) general amplification of DNA molecules in a multiple of droplets each containing less than 0.5 target DNA molecule on average ( | 2020-12-24 |
20200399681 | ASSAY FOR DETECTION OF ANDROGEN RECEPTOR VARIANTS - Sensitive assay methods are described herein that involve (a) capturing circulating cancer cells (e.g., by any method); (b) extracting mRNA and (c) detecting and quantifying each of full-length androgen receptor (AR-FL), androgen receptor variant 7 (AR-V7), and androgen receptor variant 5,6,7 (AR-V567) in parallel digital droplet PCR assays. Additional methods are described herein for detecting and/or isolating circulating cancer cells by selecting for cells that express transferrin receptor. | 2020-12-24 |
20200399682 | Oligonucleotide, Set of Oligonucleotides, Method for Simultaneous Detection of Neisseria Meningitidis, Streptococcus Pneumoniae and Haemophilus Influenzae, and Kit - The present invention provides a real-time PCR method that allows in a single step the simultaneous detection of etiological agents of bacterial meningitis, more specifically, | 2020-12-24 |
20200399683 | Composition and Methods For Affinity Directed Enrichment of Rare Species - Compositions and methods for the selective extraction of rare molecular species from a mixture containing a predominance of related molecular species, and their subsequent release are provided. Compositions include a segregating probe having a target-specific targeting portion, a protecting portion, a scissile or cleavable site or portion, and a capture portion. Complex formation between the targeting portion and the target rare species results in protection of the cleavable site. Such complexes remain intact through a cleavage step directed to the cleavable site or portion of the segregating probe. While complex formation can occur between a segregating probe and a related, but non-target, species the cleavable site is not protected in such complexes. A subsequent capture step directed to the capture portion selectively captures or segregates the target rare species from the general milieu, which can be removed by washing. Subsequent release of the target rare species from the segregating probe provides a solution enriched in the target rare species. | 2020-12-24 |
20200399684 | PATTERNED FLOW-CELLS USEFUL FOR NUCLEIC ACID ANALYSIS - Provided is a surface having metal regions and an interstitial region having a composition that differs from the metal regions, wherein a continuous gel layer coats the surface across the metal regions and the interstitial regions. Nucleic acids or other analytes can be attached to the continuous gel layer such that a greater amount is attached over the metal regions than over the interstitial region. Also provided are methods for making such surfaces. Methods are also provided for making an array of nucleic acids or other analytes using such surfaces. | 2020-12-24 |
20200399685 | METHODS FOR DETECTION OF ANTIBIOTIC RESISTANT H.PYLORI - The present disclosure provides methods and materials for determining if antibiotic resistant | 2020-12-24 |
20200399686 | METHOD AND APPARATUS FOR SIMULTANEOUS TARGETED SEQUENCING OF DNA, RNA AND PROTEIN - Provided herein are methods and systems for the simultaneous targeted detection and sequencing of DNA, RNA, and Protein. In typical embodiments, the DNA, RNA, and Proteins are detected, characterized, and sequenced using just a single mammalian cell. One embodiment of detecting and characterizing DNA, RNA, or protein from a mammalian cell includes encapsulating a single cell in a drop and performing a protease digest on the encapsulated cell drop, performing a reverse transcriptase reaction; performing a droplet merger with barcoding PCR reagents and barcoding beads; performing a PCR reaction to attach the cell barcodes to the DNA targeted amplicons, RNA targeted amplicons, and protein tag amplicons, where all amplicons from the same emulsion contain the same cell barcode; and detecting and characterizing a DNA, RNA, or protein amplicon by sequencing the cell barcode incorporated into each amplicon. | 2020-12-24 |
20200399687 | Spatially Distinguished, Multiplex Nucleic Acid Analysis of Biological Specimens - A method for spatially tagging nucleic acids of a biological specimen, including steps of (a) providing a solid support comprising different nucleic acid probes that are randomly located on the solid support, wherein the different nucleic acid probes each includes a barcode sequence that differs from the barcode sequence of other randomly located probes on the solid support; (b) performing a nucleic acid detection reaction on the solid support to locate the barcode sequences on the solid support; (c) contacting a biological specimen with the solid support that has the randomly located probes; (d) hybridizing the randomly located probes to target nucleic acids from portions of the biological specimen; and (e) modifying the randomly located probes that are hybridized to the target nucleic acids, thereby producing modified probes that include the barcode sequences and a target specific modification, thereby spatially tagging the nucleic acids of the biological specimen. | 2020-12-24 |
20200399688 | METHOD AND SYSTEM FOR SUPERCOILING DNA - A method for supercoiling DNA, e.g. negatively supercoiling DNA, is disclosed. In an initial state, at least part of a DNA molecule is torsionally constrained and associated with a first linking number. The at least part of the DNA molecule has a first end connected to a first body and a second end connected to a second body. The method comprises increasing a distance between the first body and the second body for inducing a torque in the at least part of the DNA molecule and for bringing the at least part of the DNA molecule from the initial state into an intermediate state. In the intermediate state the at least part of the DNA molecule is temporarily torsionally unconstrained for at least partially releasing the induced torque for changing, e.g. decreasing, the first linking number. The method further comprises decreasing the distance between the first and second body for bringing the at least part of the DNA molecule from the intermediate state into a further state in which the at least part of the DNA molecule is torsionally constrained and associated with a second linking number different from the first linking number. | 2020-12-24 |
20200399689 | METHODS OF DETECTING NUCLEIC ACID SEQUENCES WITH HIGH SPECIFICITY - The invention relates to methods of detecting nucleic acids, including methods of detecting one or more target nucleic acid sequences in multiplex branched-chain DNA assays, are provided. Nucleic acids captured on a solid support or suspending cells are detected, for example, through cooperative hybridization events that result in specific association of a label with the nucleic acids. The invention further relates to methods to improve probe hybridization specificity and their application in genotyping. The invention also relates to in situ detection of mis-joined nucleic acid sequences. The invention relates to reducing false positive signals and improve signal-to-background ratio in hybridization-based nucleic acid detection assay. The invention further relates to method to improve specificity in hybridization based nucleic acid using co-location probes. Compositions, tissue slides, sample of suspended cells, kits, and systems related to the methods are also described. | 2020-12-24 |
20200399690 | COMPOSITIONS AND METHODS FOR SELECTION OF NUCLEIC ACIDS - Methods are provided for reducing the complexity of a population of nucleic acids prior to performing an analysis of the nucleic acids, e.g., sequence analysis. The methods result in a subset of the initial population enriched for a target region, which is typically located within one or more target fragments. The methods are particularly useful for analyzing populations having a high degree of complexity, e.g., chromosomal-derived DNA, whole genomic DNA, or mRNA populations. | 2020-12-24 |
20200399691 | SAMPLE PREPARATION METHODS, SYSTEMS AND COMPOSITIONS - The disclosure provides methods, compositions, systems, and kits for the concurrent detection and analysis of different structural and chemical forms of nucleic acids in a sample. | 2020-12-24 |
20200399692 | MODIFIED NUCLEOTIDES - The invention provides modified nucleotide or nucleoside molecule comprising a purine or pyrimidine base and a ribose or deoxyribose sugar moiety having a removable 3′-OH blocking group covalently attached thereto, such that the 3′ carbon atom has attached a group of the structure —O—Z wherein Z is any of —C(R′)2-O—R″, —C(R′)2-N(R″)2, —C(R′)2-N(H)R″, —C(R′)2-S—R″ and —C(R′)2-F, wherein each R″ is or is part of a removable protecting group; each R′ is independently a hydrogen atom, an alkyl, substituted alkyl, arylalkyl, alkenyl, alkynyl, aryl, heteroaryl, heterocyclic, acyl, cyano, alkoxy, aryloxy, heteroaryloxy or amido group, or a detectable label attached through a linking group; or (R′)2 represents an alkylidene group of formula ═C(R′″)2 wherein each R′″ may be the same or different and is selected from the group comprising hydrogen and halogen atoms and alkyl groups; and wherein said molecule may be reacted to yield an intermediate in which each R″ is exchanged for H or, where Z is —C(R′)2-F, the F is exchanged for OH, SH or NH2, preferably OH, which intermediate dissociates under aqueous conditions to afford a molecule with a free 3′OH; with the proviso that where Z is —C(R′)2-S—R″, both R′ groups are not H. | 2020-12-24 |
20200399693 | NANOPORE ASSEMBLIES AND USES THEREOF - The disclosure provides a nanopore system assembled with non-membrane proteins for detecting analytes. Also disclosed are the methods, kits, and detection devices employing the disclosed nanopore system. The nanopore system has a wide variety of applications, including single molecule detection, DNA/RNA/peptide sequencing, sensing of chemicals, biological reagents, and polymers, and disease diagnosis. | 2020-12-24 |
20200399694 | METHODS OF LABELLING NUCLEIC ACIDS - A method of labelling a nucleic acid of interest (NAOI) is provided. In some embodiments, the method may comprise contacting a sample comprising the nucleic acid of interest with a pool of oligonucleotides, the pool comprising oligonucleotides having at least 5 different lengths; and attaching an oligonucleotide from the pool on to one or each end of the nucleic acid of interest, wherein attachment of an oligonucleotide moves the read start and/or stop coordinate when the labelled NAOI is sequenced. | 2020-12-24 |
20200399695 | NUCLEIC ACID ANALYSIS BY RANDOM MIXTURES OF NON-OVERLAPPING FRAGMENTS - The invention provides methods and kits for ordering sequence information derived from one or more target polynucleotides. In one aspect, one or more tiers or levels of fragmentation and aliquoting are generated, after which sequence information is obtained from fragments in a final level or tier. Each fragment in such final tier is from a particular aliquot, which, in turn, is from a particular aliquot of a prior tier, and so on. For every fragment of an aliquot in the final tier, the aliquots from which it was derived at every prior tier is known, or can be discerned. Thus, identical sequences from overlapping fragments from different aliquots can be distinguished and grouped as being derived from the same or different fragments from prior tiers. When the fragments in the final tier are sequenced, overlapping sequence regions of fragments in different aliquots are used to register the fragments so that non-overlapping regions are ordered. In one aspect, this process is carried out in a hierarchical fashion until the one or more target polynucleotides are characterized, e.g. by their nucleic acid sequences, or by an ordering of sequence segments, or by an ordering of single nucleotide polymorphisms (SNPs), or the like. | 2020-12-24 |
20200399696 | Compositions and Methods for Detecting C1orf43 Nucleic Acid - This disclosure provides oligomers, combinations of oligomers, compositions, kits, uses, and methods for detecting a C1orf43 nucleic acid, such as C1orf43 mRNA, such as human C1orf43 mRNA, in a sample. | 2020-12-24 |
20200399697 | TYPE V CRISPR/CAS EFFECTOR PROTEINS FOR CLEAVING SSDNAS AND DETECTING TARGET DNAS - Provided are compositions and methods for detecting a target DNA (double stranded or single stranded) in a sample. In some embodiments, a subject method includes: (a) contacting the sample with: (i) a type V CRISPR/Cas effector protein (e.g., a Cas12 protein such as Cas12a, Cas12b, Cas12c, Cas12d, Cas12e); (ii) a guide RNA (comprising a region that binds to the type V CRISPR/Cas effector protein, and a guide sequence that hybridizes with the target DNA); and (iii) a detector DNA that is single stranded (i.e., a “single stranded detector DNA”) and does not hybridize with the guide sequence of the guide RNA; and (b) measuring a detectable signal produced by cleavage (by the type V CRISPR/Cas effector protein) of the single stranded detector DNA. Also provided are compositions and methods for cleaving single stranded DNAs (e.g., non-target ssDNAs), e.g., inside of a cell. | 2020-12-24 |